Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays

Group 1 - BioMarin Pharmaceutical Inc. is considered one of the best cheap stocks to buy currently, with Barclays initiating coverage and assigning an "Overweight" rating and a target price of $80, indicating a 41.5% upside from the current price [1][2] - Barclays highlights the company's acquisition plans and strong fundamentals as key reasons for the overweight rating [1] - BioMarin is in the process of acquiring Amicus Therapeutics, Inc., and has finalized a $2 billion senior secured term loan B to fund this acquisition, alongside an $800 million loan and a $600 million revolving credit line [2] Group 2 - Among analysts covering BioMarin, 21 out of 27 (approximately 78%) have a "Buy" rating, while the remaining 6 (around 22%) recommend a "Hold" [2] - The median target price for BioMarin is $96.50, with a high estimate of $122, suggesting an upside of 70.68% (or 115.78% based on the highest estimate) [2] - BioMarin Pharmaceutical Inc. is a global biotech company focused on rare genetic diseases, founded in 1997 and headquartered in San Rafael, California [2]